Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 2/20 | 0.40 |
| ▸ | NQO2 | P16083 | 2/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.37 |
| ▸ | CETP | P11597 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21360734 | 0.74 | BRD4 (0.38) | PIN1NQO2MTNR1AMTNR1BCETP | |
| SCHEMBL22477091 | 0.72 | HTR2A (0.51) | NQO2MTNR1AMTNR1BDRD2 | |
| SCHEMBL25675770 | 0.66 | DRD2 (0.50) | DRD2 | |
| SCHEMBL14367929 | 0.66 | DRD2 (0.50) | DRD2 | |
| SCHEMBL14169776 | 0.66 | DRD2 (0.50) | DRD2 | |
| SCHEMBL19419825 | 0.66 | DRD2 (0.50) | DRD2 | |
| SCHEMBL31040167 | 0.66 | NQO2 (0.36) | NQO2MTNR1AMTNR1BDRD2ADRA1A | |
| SCHEMBL20170607 | 0.64 | OPRM1 (0.37) | NQO2MTNR1AMTNR1B | |
| SCHEMBL20170652 | 0.64 | OPRM1 (0.37) | NQO2MTNR1AMTNR1B | |
| SCHEMBL15682035 | 0.63 | CA2 (0.47) | NQO2TSHRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3401306-B1 | DEZOCINE ANALOGUE | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2020-09-30 | — | — | EP | disclosed |
| US-10414718-B2 | Dezocine analogue | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2019-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414718-B2 | Dezocine analogue | DDO, DDC, DAO | PIN1 329/4885NQO2 502/4885MTNR1A 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.